Atomo Diagnostics: Funding, Investors & Team (Sep 2026)
Atomo Diagnostics, a medical device company based in Sydney, Australia, has offices in South Africa and the United Kingdom. The company was founded on the belief that healthcare products offering greater convenience, simplicity, and user experience can be highly disruptive and successful in the commercial market. In 2013, Atomo introduced AtomoRapid, a range of professional tests designed for fast and accurate results in clinical and community settings. The AtomoRapid HIV test received the Best in Show award at the Medical Device Excellence Awards (MDEA) in 2014, and Atomo was recognized as the Australian Emerging Company of the Year by Johnson & Johnson Innovation. Atomo is dedicated to improving early detection and treatment of infectious and chronic diseases by providing safer, more accurate, and more accessible testing options. For more information on the company and its products, visit www.atomodiagnostics.com.
Atomo Diagnostics has raised $1.6M across 1 funding round on record, the most recent an undisclosed round of $1.6M announced in Oct 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Atomo Diagnostics Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Atomo Diagnostics Funding Rounds
Atomo Diagnostics Founders and Leadership Team
Contact details for the Atomo Diagnostics team: 1 of 1 has an email address on file.
Start 14-day free trial →Atomo Diagnostics Funding Compared to Other Biotechnology Startups
Atomo Diagnostics' latest round of $1.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Atomo Diagnostics in Biotechnology and Leichhardt
Companies Similar to Atomo Diagnostics
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Atomo Diagnostics Funding FAQs
What does Atomo Diagnostics do?
Atomo Diagnostics, a medical device company based in Sydney, Australia, has offices in South Africa and the United Kingdom. The company was founded on the belief that healthcare products offering greater convenience, simplicity, and user experience can be highly disruptive and successful in the commercial market. In 2013, Atomo introduced AtomoRapid, a range of professional tests designed for fast and accurate results in clinical and community settings. The AtomoRapid HIV test received the Best in Show award at the Medical Device Excellence Awards (MDEA) in 2014, and Atomo was recognized as the Australian Emerging Company of the Year by Johnson & Johnson Innovation. Atomo is dedicated to improving early detection and treatment of infectious and chronic diseases by providing safer, more accurate, and more accessible testing options. For more information on the company and its products, visit www.atomodiagnostics.com.
How much funding has Atomo Diagnostics raised?
Atomo Diagnostics has raised $1.6M across 1 round on record. The most recent is an undisclosed round of $1.6M announced in Oct 2024.
When did Atomo Diagnostics last raise funding?
Atomo Diagnostics' most recent funding round on record is an undisclosed round of $1.6M, announced in Oct 2024.
Who founded Atomo Diagnostics?
FundedIQ lists John Kelly (Founder) at Atomo Diagnostics.
Where is Atomo Diagnostics headquartered?
Atomo Diagnostics is based in Leichhardt, New South Wales, Australia.
How many employees does Atomo Diagnostics have?
Atomo Diagnostics is in the 11-50 employee band.
How does Atomo Diagnostics' funding compare to other Biotechnology startups?
Atomo Diagnostics' latest round of $1.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Atomo Diagnostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Atomo Diagnostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.